{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-281531","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.065372+00:00","generated_at":"2026-05-16T19:52:21.063059+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Iterum Therapeutics Q3 2025: ORLYNVAH launch nets $0.4M revenue; cash runway extended to Q2 2026","bullets":["Net product revenue of $0.4M from ORLYNVAH launch in August 2025; 2026 sales guidance $5M-$15M.","Cash and equivalents $11.0M as of Sep 30, 2025; additional $2.6M raised Oct-Nov 2025 extends runway into Q2 2026.","GAAP net loss $9.0M ($0.81 diluted EPS); non-GAAP net loss $7.3M vs. $6.1M and $4.8M in Q3 2024.","SG&A expenses rose to $6.5M from $1.8M YoY due to commercialization; R&D fell to $1.3M.","Granted patents in China and Mexico covering sulopenem combinations; IDWeek posters presented."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-281531","json":"https://secwatch.observer/filing/0001193125-25-281531.json","markdown":"https://secwatch.observer/filing/0001193125-25-281531.md","text":"https://secwatch.observer/filing/0001193125-25-281531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/0001193125-25-281531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-20251114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:52:21.063059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}